Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Total 13F shares
-
8,426,635
-
Share change
-
+8,426,133
-
Total reported value
-
$54,262,353
-
Put/Call ratio
-
8.8%
-
Price per share
-
$6.44
-
Number of holders
-
41
-
Value change
-
+$54,259,120
-
Number of buys
-
40
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q3 2022
As of 30 Sep 2022,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,426,635 shares.
The largest 10 holders included
Artal Group S.A., Bain Capital Life Sciences Investors, LLC, Flagship Pioneering Inc., Avidity Partners Management LP, Ally Bridge Group (NY) LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, CVI Holdings, LLC, DAFNA Capital Management LLC, and FMR LLC.
This page lists
41
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.